title: The effects of ghrelin/GHSs on AVP mRNA expression and release in cultured hypothalamic cells in rats.
abstract: Ghrelin, the endogenous ligand for growth hormone secretagogues (GHSs) receptor (GHS-R), increases adrenocorticotropin (ACTH) and cortisol (corticosterone) as well as GH secretion in humans and animals. However, the site of GHSs action to induce ACTH secretion is not fully understood. To clarify the mechanisms of the action of ghrelin/GHSs on ACTH secretion, we analyzed the effects of KP-102 and ghrelin on the mRNA expression and release of corticotropin releasing factor (CRF) and arginine vasopressin (AVP), ACTH secretagogues, in monolayer-cultured hypothalamic cells of rats. Incubation of cells with KP-102 for 4h and 8h and with ghrelin for 4h significantly increased AVP mRNA expression and release without changing CRF mRNA expression. CRF levels in culture media were undetectable. Suppression of GHS-R expression by siRNA blocked ghrelin- and KP-102-induced AVP mRNA expression and release. NPY significantly increased AVP mRNA expression and release. Furthermore, treatment of cells with anti-NPY IgG blocked KP-102-induced AVP mRNA expression and release. We previously reported that KP-102 significantly increases NPY mRNA expression in cultured hypothalamic cells. Taken together, these results suggest that ACTH secretion by ghrelin/GHSs is induced mainly through hypothalamic AVP, and that NPY mediates the action of ghrelin/GHSs.
authors.affiliation: Department of Physiology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan. taknemo@nms.ac.jp
authors.forename: Takahiro
authors.initials: T
authors.lastname: Nemoto
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Sugihara
authors.forename: Asuka
authors.initials: A
authors.lastname: Mano
authors.forename: Toshiko
authors.initials: T
authors.lastname: Kano
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Shibasaki
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000096:biosynthesis; D000818:Animals; D000831:Animals, Newborn; D000906:Antibodies / Q000494:pharmacology; D001127:Arginine Vasopressin / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D002478:Cells, Cultured; D003345:Corticosterone / Q000096:biosynthesis; D003346:Corticotropin-Releasing Hormone / Q000235:genetics / Q000378:metabolism*; D020868:Gene Silencing; D054439:Ghrelin / Q000494:pharmacology*; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D009478:Neuropeptide Y / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D009842:Oligopeptides / Q000494:pharmacology*; D012333:RNA, Messenger / Q000032:analysis; D034741:RNA, Small Interfering / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D054440:Receptors, Ghrelin
chemical_list: D000906:Antibodies; D054439:Ghrelin; D009478:Neuropeptide Y; D009842:Oligopeptides; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D054440:Receptors, Ghrelin; D001127:Arginine Vasopressin; D000324:Adrenocorticotropic Hormone; D013006:Growth Hormone; D003346:Corticotropin-Releasing Hormone; C091874:growth hormone-releasing peptide-2; D003345:Corticosterone